



# Influenza vaccine

## Revisiting Old and Addressing Current Issues

Dr. Leilani T. Sanchez, DPPS, DPIDSP

Manila, 18 February 2016

~~To Be~~ **QIV**  
**Or**  
~~Not To Be~~ **QIV**  
by  
William  
Shakespeare




Influenza B pose less of a disease burden than Influenza A

There is only one B strain circulating every influenza season

Influenza B is not as severe as Influenza A



# Influenza B




- Influenza B predominately circulates in human populations
- There are 2 antigenically and genetically distinct lineages
  - B/Victoria/2/87- like (**Victoria lineage**)
  - B/Yamagata/16/88-like (**Yamagata lineage**)
- Antibody responses to influenza B infection in children are lineage specific, with no cross reactivity between lineages
- Children accumulated natural immunity to influenza B more slowly than to influenza A.

Rota PA, Wallis TR, Harmon MW, Rota JS, Kendal AP, Nerome K. Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. *Virology*. 1990;175(1):59-68

Bodewes R, de Mutsert G, van der Klis FR, Ventresca M, Wilks S, Smith DJ, et al. Prevalence of antibodies against seasonal influenza A and B viruses in children in Netherlands. *Clin Vaccine Immunol* 2011; 18:469-76

# WHO Review of the 2015 influenza season in the southern hemisphere

Map 1 **Distribution of influenza virus subtypes by influenza transmission zone, May 2015 to September 2015**  
 Carte 1 **Distribution des sous-types de virus grippaux par zones de transmission de la grippe, mai 2015-septembre 2015**



Source: WHO Global Influenza Programme (data in WHO headquarters as of 30 September 2015). The data used come from: FluNet ([www.who.int/flu-net](http://www.who.int/flu-net)), WHO regional offices and/or ministry of health websites. – Programme mondial de lutte contre la grippe de l’OMS (données disponibles au siège de l’OMS, 30 septembre 2015): les données utilisées proviennent de FluNet ([www.who.int/flu-net](http://www.who.int/flu-net)), des sites Internet des Bureaux régionaux de l’OMS et/ou des Ministères de la Santé.

Note: the available country data were joined in larger geographical areas with similar influenza transmission patterns to be able to give an overview ([www.who.int/influenza/surveillance\\_monitoring/updates/EN\\_GIP\\_influenza\\_transmission\\_zones.pdf](http://www.who.int/influenza/surveillance_monitoring/updates/EN_GIP_influenza_transmission_zones.pdf)). – Note: les données disponibles relatives aux pays ont été regroupées par zones géographiques plus larges où les modalités de transmission sont similaires de manière à fournir un tableau synoptique ([www.who.int/influenza/surveillance\\_monitoring/updates/EN\\_GIP\\_influenza\\_transmission\\_zones.pdf](http://www.who.int/influenza/surveillance_monitoring/updates/EN_GIP_influenza_transmission_zones.pdf)).

The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. – Les appellations employées dans la présente publication et la présentation des données qui y figurent n’impliquent de la part de l’Organisation mondiale de la Santé aucune prise de position quant au statut juridique des pays, territoires, villes ou zones, ou de leurs autorités, ni quant au tracé de leurs frontières ou limites. Les lignes en pointillés sur les cartes représentent des frontières approximatives dont le tracé peut ne pas avoir fait l’objet d’un accord définitif.

© WHO 2015. All rights reserved. – © OMS 2015. Tous droits réservés.

# Epidemiological and Virological Characteristics of Influenza in the Western Pacific Region, 2006- 2010

**Table 2.** Specimens tested and specimens positive for influenza by type/subtype/lineage in Western Pacific Region countries, 2006–2010. <sup>^</sup>


|  | 2006 <sup>o</sup> | 2007 <sup>1</sup> | 2008 <sup>2</sup> | 2009 <sup>3</sup> | 2010 <sup>3</sup> |
|--|-------------------|-------------------|-------------------|-------------------|-------------------|
| Number of specimens tested                   | 65,103            | 92,939            | 94,274            | 366,164           | 307,584           |
| Number of influenza positive specimens       | 7,425 (11.4%)     | 11,143 (12.0%)    | 11,025 (11.7%)    | 115,554 (31.6%)   | 51,573 (16.8%)    |
| Influenza positive specimens by type/subtype |                   |                   |                   |                   |                   |
| Influenza A total                            | 4,393             | 7,297             | 7,426             | 110,668           | 26,008            |
| A(H1)  | 2,952             | 907               | 4,241             | 6,307             | 31                |
| A(H1N1)pdm09                                 | 0                 | 0                 | 0                 | 74,252            | 10,728            |
| A(H3)  | 918               | 5,397             | 1,961             | 19,018            | 12,276            |
| A(subtyping not performed)                   | 523               | 993               | 1,224             | 11,091            | 2,973             |
| Influenza B total                            | 3,032             | 3,846             | 3,599             | 4,886             | 25,565            |
| B(Victoria)                                  | 744               | 927               | 827               | 1,532             | 4,505             |
| B(Yamagata)                                  | 76                | 1,642             | 1,360             | 235               | 954               |
| B(lineage not determined)                    | 2,212             | 1,277             | 1,412             | 3,119             | 20,106            |

Members of the Western Pacific Region Global Influenza Surveillance and Response System (2012) Epidemiological and Virological Characteristics of Organization, 2006–2010. PLoS ONE 7(5): e37568. doi:10.1371/Influenza in the Western Pacific Region of the World Health journal.pone.0037568


# Influenza in the Philippines

G

PHILIPPINES




Influenza A




Influenza B

Saha et al. (2016) Divergent seasonal patterns of influenza types A and B across latitude gradient in Tropical Asia. *Influenza and Other Respiratory Viruses* DOI: 10.1111/irv.12372

# Influenza in the Philippines



Influenza A




Influenza B

Saha et al. (2016) Divergent seasonal patterns of influenza types A and B across latitude gradient in Tropical Asia. *Influenza and Other Respiratory Viruses* DOI: 10.1111/irv.12372



# Influenza in the Philippines

## Circulating Influenza B lineages 2003 -2013



# Burden of Influenza B

- Although influenza B causes disease in all age groups, its incidence related to influenza A appears to be highest among older children and young adults.
- While influenza B causes mortality in all age groups, it appears to be a disproportionate cause of pediatric influenza deaths

Among US pediatric influenza deaths between 2004 and 2011, excluding the 2009---2010 pandemic, 22% to 44% of deaths each season were confirmed to be influenza B-related

Ambrose, C. and M. Levin, The rationale for quadrivalent influenza vaccines. *Human Vaccines & Immunotherapeutics*, 2012. 8(1): p. 81-88.  
Seasonal flu. Atlanta, GA: Centers for Disease Control and Prevention; 2011. Available at: <http://www.cdc.gov/> flu.  
Glezen WP et al. The Burden of Influenza B: A Structured Literature Review. *Am J Public Health*. 2013 Mar;103(3):e43-51

# Burden of Influenza B

- The influenza B attributable primary respiratory and circulatory hospitalization rate in the United States was a substantial
  - Influenza A(H3N2) 99.0 per 100,000
  - Influenza B 81.4 per 100,000
  - Influenza A (H1N1) 55.9 per 100,000
- In Hong Kong, influenza B hospitalization rates varied by age
  - Highest rates observed in 2 – 4 year olds (43.5 per 10,000)

Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. *JAMA*. 2004;292(11):1333---1340  
Chiu SS, Chan KH, Chen H, et al. Virologically confirmed population-based burden of hospitalization caused by influenza A and B among children in Hong Kong. *Clin Infect Dis*. 2009;49(7):1016---1021.  
Glezen WP et al. The Burden of Influenza B: A Structured Literature Review. *Am J Public Health*. 2013 Mar;103(3):e43-51

# Influenza vaccines locally available

| Name             | Brand  | Type             | Preparation      |
|------------------|--------|------------------|------------------|
| <b>Influvac</b>  | Abbott | TIV Sub-unit     | 0.5 ml           |
| <b>Fluarix</b>   | GSK    | TIV Split virion | 0.5 ml           |
| <b>Vaxigrip</b>  | Sanofi | TIV Split virion | 0.5 ml           |
| <b>FluQuadri</b> | Sanofi | QIV Split virion | 0.5ml and 0.25ml |




# WHO recommendations on the composition of influenza virus vaccines

| Year             | Northern Hemisphere  | Year        | Southern Hemisphere   | Comment          |
|------------------|--|-------------|---|------------------|
| <b>2013-2014</b> | an A/California/7/2009 (H1N1)pdm09-like virus;<br>an A/Texas/50/2012 (H3N2)-like virus;<br>a B/Massachusetts/2/2012-like virus                                       | <b>2014</b> | <b>an A/California/7/2009 (H1N1)pdm09-like virus;</b><br>an A/Texas/50/2012 (H3N2)-like virus;<br>a B/Massachusetts/2/2012-like virus   | Same             |
| <b>2014-2015</b> | an A/California/7/2009 (H1N1)pdm09-like virus;<br>an A/Texas/50/2012 (H3N2)-like virus;<br>a B/Massachusetts/2/2012-like virus<br>a B/Brisbane/60/2008-like virus    | <b>2015</b> | <b>an A/California/7/2009 (H1N1)pdm09-like virus;</b><br>an A/Switzerland/9715293/2013 (H3N2)-like virus;<br><b>a B/Phuket/3073/2013-like virus</b><br><b>a B/Brisbane/60/2008-like virus</b> | 2/4<br>different |
| <b>2015-2016</b> | an A/California/7/2009 (H1N1)pdm09-like virus<br>an A/Switzerland/9715293/2013 (H3N2)-like virus<br>a B/Phuket/3073/2013-like virus<br>B/Brisbane/60/2008-like virus | <b>2016</b> | <b>an A/California/7/2009 (H1N1)pdm09-like virus</b><br>an A/Hong Kong/4801/2014 (H3N2)-like virus<br><b>a B/Brisbane/60/2008-like virus</b><br><b>a B/Phuket/3073/2013-like virus</b>        | 1/4<br>different |



# Dosing in Children Aged 6 months – 8 years old




\* The two doses need not have been received during the same season or consecutive seasons.

† Doses should be administered ≥4 weeks apart.

**Medscape**

Source: MMWR © 2015 Centers for Disease Control and Prevention (CDC)

# Vaccination of Persons with a History of Egg Allergy



- Persons with a history of egg allergy who have experienced only hives after exposure to egg should receive flu vaccine
- A previous severe allergic reaction to influenza vaccine, regardless of the component suspected of being responsible for the reaction, is a contraindication to future receipt of the vaccine.

